Here's the relevant data (bottom paragraph). Note that the results are not "stat sig". http://investors.galenabiopharma.com/releasedetail.cfm?ReleaseID=620971 h

Here's the relevant data (bottom paragraph). Note that the results are not "stat sig". http://investors.galenabiopharma.com/releasedetail.cfm?ReleaseID=620971 http://investors.galenabiopharma.com/releasedetail.cfm?Relea... I'm surprised this story is being upvoted here. The original article seems like a puff piece and cancer vaccines have quite a checkered history. Also, Galena's press releases related to the vaccine seem a little scammy (e.g., "Galena Biopharma Announces Investigational New Drug Approval for Phase 2 Trial for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (trastuzumab)"... The title is trying to play off of the phrase "new drug approval" when in reality, they simply received approval to run the trial. A total of 187 patients were enrolled in the combined trials (vaccine=108, control=79). Patients enrolled in the trial were node positive or high-risk node negative breast cancer patients with any level of HER2 expression (IHC 1+, 2+, or 3+), and rendered disease-free after standard adjuvant therapies. With 60 months median follow-up, the vaccine group experienced a 10.6% recurrence rate compared to 20.3% in the control group (48% risk reduction, p=0.098). Recurrence rates for vaccine and control patients with different disease features (nodal status, HER2 expression, tumor grade, and hormone receptor status) were also analyzed.